Sign In
Buy GNMSF
$232.50
+0.160 (+0.0688%)
At Close: Jun 03, 2026
Genmab A/S (GMAB) Q3 2024 Earnings Conference Call Transcript
04:38pm, Saturday, 09'th Nov 2024
Genmab A/S (GMAB) Q3 2024 Earnings Conference Call November 6, 2024 12:00 PM ET Company Participants Jan van de Winkel - CEO Brad Bailey - EVP and Chief Commercial Officer Anthony Pagano - CFO Judith
Grant of Restricted Stock Units and Warrants to Employees in Genmab
03:17pm, Thursday, 26'th Sep 2024
Company Announcement COPENHAGEN, Denmark; September 26, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 23,954 restricted stock units and 13,915 warrants to employee
Capital Increase in Genmab as a Result of Employee Warrant Exercise
04:06pm, Tuesday, 10'th Sep 2024
Company Announcement COPENHAGEN, Denmark; September 10, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 11,729 shares as a consequence of the exercise of employee warrants. The i
Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
12:26pm, Monday, 26'th Aug 2024
Media Release COPENHAGEN, Denmark; August 26, 2024 Genmab A/S (Nasdaq: GMAB ) a nnounced today that its Chief Executive Officer Jan van de Winkel, Ph.D. and Chief Financial Officer Anthony Pagano will
Genmab: Strong H1 2024 Performance, Partner BioNTech Gives Up On Acasunlimab
11:55am, Friday, 23'rd Aug 2024
Genmab's stock continues to struggle despite the strong progress of the company's commercial portfolio in the first half of the year. Epkinly is now FDA-approved for third-line+ follicular lymphoma, w
Genmab Announces Changes to its Executive Committee
09:00am, Friday, 16'th Aug 2024
Media Release COPENHAGEN, Denmark; August 16, 2024 Rayne Waller joins as Executive Vice President and Chief Technology Officer Brad Bailey appointed as Executive Vice President and Chief Commercial Of
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
02:53pm, Tuesday, 13'th Aug 2024
Company Announcement COPENHAGEN, Denmark; August 13, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,
Capital Increase in Genmab as a Result of Employee Warrant Exercise
02:51pm, Tuesday, 13'th Aug 2024
Company Announcement COPENHAGEN, Denmark; August 13, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 28,193 shares as a consequence of the exercise of employee warrants. The incr
Genmab Announces Financial Results for the First Half of 2024
11:03am, Thursday, 08'th Aug 2024
August 8, 2024 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2024 Highlights Completed acquisition of ProfoundBio Inc (ProfoundBio), granting Genmab worldwide rights to t
Genmab Updates 2024 Financial Guidance
11:00am, Thursday, 08'th Aug 2024
Company Announcement Genmab updates its 2024 financial guidance Increase in revenue driven by higher royalties and reimbursement revenue Increase in operating profit excluding acquisition and integrat
Genmab Takes Full Control of Acasunlimab Development Program
05:50am, Monday, 05'th Aug 2024
Company Announcement Genmab to assume sole responsibility for the continued development and potential commercialization of acasunlimab BioNTech has opted not to participate in the further development
Wall Street Analysts Think Genmab (GMAB) Could Surge 45.08%: Read This Before Placing a Bet
10:56am, Friday, 02'nd Aug 2024
The consensus price target hints at a 45.1% upside potential for Genmab (GMAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r
All You Need to Know About Genmab (GMAB) Rating Upgrade to Strong Buy
01:00pm, Monday, 29'th Jul 2024
Genmab (GMAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Wall Street Analysts Believe Genmab (GMAB) Could Rally 52.33%: Here's is How to Trade
10:56am, Wednesday, 17'th Jul 2024
The consensus price target hints at a 52.3% upside potential for Genmab (GMAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024
06:25am, Wednesday, 17'th Jul 2024
Company Announcement Net sales of DARZALEX ® in the second quarter of 2024 totaled USD 2,878 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN,
